← Back to patent-cliff list
Sunvozertinib
Tier C — Watch / tradeSunvozertinib
-
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EGFR exon 20 insertion mutations, EGFR L858R, EGFR T790M, HER2 exon 20 insert mutations
Brand：ZEGFROVY
Indications (approved)：Non-small cell lung cancer
Regional status
US
Approved
2025-07-02
EU
Phase III
2022-12-13
China
Approved
2023-08-22
Japan
Phase II
2019-07-09
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sunvozertinib?
Approved indications include: Non-small cell lung cancer.
When does the Sunvozertinib patent expire?
No public expiry year is available for Sunvozertinib yet; this page updates once verified.
How do I get a quote for Sunvozertinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01